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INTRODUCTION

DIFFERENTIAL DIAGNOSIS

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired,
life-threatening hematopoietic stem cell disorder
characterized by the triad of hemolytic anemia, thrombosis,
and impaired bone marrow function. PNH arises due to an
acquired mutation in the synthesis of the glycosylphosphatidylinositol (GPI) anchor protein, which leads to a
deficiency of complement regulatory proteins and
unregulated complement-mediated hemolysis.1 With a
reported incidence of 1 to 10 cases per million and a 3-5%
risk of developing leukemia, new therapeutic advances
have emerged to decrease the 10-year mortality associated
with PNH. 2,3 Here, we discuss the presentation of a
59-year-old male with PNH, strategies to diagnose this
rare condition, and therapeutic challenges regarding
anticoagulation in these patients.

The differential diagnosis for fever, headache, altered
mental status, anemia, thrombocytopenia, and indirect
hyperbilirubinemia includes both intrinsic and extrinsic
causes of hemolysis. Intrinsic hemolytic causes include
hemoglobinopathies, hereditary spherocytosis, and
paroxysmal nocturnal hemoglobinuria. Extrinsic
hemolytic causes include disseminated intravascular
coagulation (DIC), antiphospholipid antibody syndrome,
thrombotic thrombocytopenic purpura (TTP), hemolyticuremic syndrome (HUS), autoimmune hemolytic anemia
(AIHA), and infections such as malaria and babesiosis.

CASE PRESENTATION
The patient is a 59-year-old Russian-speaking male with a
past medical history significant for diabetes and
hypertension who presented to the Emergency
Department (ED) with two days of fever, headache, and
altered mental status. The headache was described as a
constant, 7/10 bilateral posterior headache that radiated
anteriorly and improved with over-the-counter
acetaminophen. His family described his altered mental
status as confusion regarding recent events and short-term
memory loss. The patient denied photophobia or neck
stiffness. He denied changes in vision, unilateral weakness,
loss of sensation, or any other focal neurological deficits.
He had no recent travel or sick contacts. He is a former
cigarette smoker (40 pack-year history) and social drinker
with no history of illicit drug use.
On admission, the patient was noted to be febrile to
103.1° F, tachycardic to 121 beats per minute, tachypneic
to 22 breaths per minute, and normotensive at 121/70.
On physical exam, he was awake, alert, and oriented to
person, place, and time but not to situation or recent
events. He was noted to have scleral icterus and
hepatomegaly. The remainder of the physical exam was
unremarkable. Labs on admission were notable for anemia
(Hemoglobin 7.7, baseline of 9.4), thrombocytopenia
(Platelet count of 108, baseline of 152), transaminitis
(AST 84, ALT 53), hyperbilirubinemia (Total Bilirubin 1.9,
Direct Bilirubin 0.7), and coagulopathy (PT 30.9, PTT 43,
INR 3.8). The patient’s renal function was within normal
limits. A CT scan of his head on initial presentation was
unremarkable.

Figure 1. Brain MRI – Day 2 of presentation. The Images demonstrate multiple foci
of recent infarction in the supratentorial and tentorial brain; and no evidence of
intracranial hemorrhage.

HOSPITAL COURSE
The patient defervesced after Day 2 of his hospitalization. As part of his infectious work-up, blood and
urine cultures were sent and demonstrated no growth.
His chest x-ray was unremarkable. A lumbar puncture
was done in the ED on arrival and was unrevealing with
glucose 80, protein 31, and no RBCs or WBCs.
Due to persistent, severe headaches and concern for
possible intracranial thrombosis, an MRI of the brain was
done and revealed multiple subacute periventricular
ischemic emboli bilaterally (Figure 1). MRV of the brain
did not show cavernous venous thromboses. MRA of
the brain did not show any clots in the Circle of Willis.
Persistent transaminitis and concern for portal vein
thrombosis resulted in a Doppler ultrasound of the
abdomen which excluded reversal of blood flow. An MRI
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of the abdomen revealed splenomegaly with splenic
infarcts, renal cortical hemosiderosis, and hepatomegaly
with altered perfusion representing hepatic sinusoidal
obstruction syndrome (SOS) (Figure 2).

Figure 2. MRI abdomen – Day 2 of persistent transaminitis. The images demonstrate
hepatomegaly with altered perfusion and attenuated but patent hepatic vasculature;
splenomegaly with splenic infarcts; and renal cortical hemosiderosis, which can be
seen with paroxysmal nocturnal hemoglobinuria.

Workup for the cause of the patient’s hemolytic anemia
included studies for antiphospholipid antibody syndrome,
TTP, DIC, HUS, hereditary spherocytosis, and AIHA—all
of which were not revealing. The fluorescein-labeled
proaerolysin (FLAER) and flow cytometry assay to look
for GPI anchor protein and CD55-59 deficient cells,
respectively, were performed. The results of the assays
were diagnostic of paroxysmal nocturnal hemoglobinuria (Table 1). A bone marrow biopsy was also
performed which showed a normocellular bone marrow
with trilineage hematopoiesis, relative erythroid
hyperplasia and rare stainable iron, and no evidence of
abnormal myeloid lymphoid, or plasma cell populations.
Non–Erythroid Cell Type

%

Granulocytes

68%

Lymphocytes

25%

Monocytes

3%

Blasts

0%

Lymphoid Cell Type

%

B Cells (CD20+)

9%

T Cells (CD3+)

82%

NK Cells (CD56+/CD3-)

7%

Kappa to Lambda ratio

1.5

CD4 to CD8 ratio

2.0

Table 1. FLAER results and differential count of total non-erythroid cells.
The B-lymphoid cells constitute 9% of all lymphoid cells and are polyclonal for
immunoglobulin light chain expression. The T-lymphoid cells constitute 82% of all
lymphoid cells and demonstrate a CD4:CD8 ratio of 2:1 Blasts are not detected.
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MANAGEMENT AND FOLLOW-UP
The patient was started on unfractionated heparin and
bridged to warfarin. On Day 6 of his hospitalization, he
began eculizumab, a humanized monoclonal antibody
that is a terminal complement inhibitor and the only known
FDA-approved treatment for PNH. After two doses of
eculizumab, the patient showed significant clinical
improvement. His headaches, mental status, hemolysis,
and transaminitis all improved. Stem cell transplantation
was deemed unnecessary as his blood counts stabilized
prior to discharge. He was discharged home on warfarin
with the plan to follow-up with hematology-oncology and
to continue receiving eculizumab as an outpatient.
A week after discharge, the patient received his third
treatment of eculizumab. The patient received the
meningococcal vaccination and the pneumococcal
vaccination due to elevated risk of infection from
encapsulated organisms following eculizumab treatment.
Eculizumab predisposes patients to life-threatening
Neisseria meningitides infections (0.5% per year), meriting
both vaccination as well as prophylactic penicillin.4 The
patient will receive lifelong anticoagulation with warfarin
(INR goal 2-3). He was scheduled to have repeat imaging
of his liver and follow up with hepatology due to his
sinusoidal obstruction syndrome.

DISCUSSION
The most common presentation of PNH is fatigue (80%),
followed by dyspnea (64%) and hemoglobinuria (62%).5
Thrombosis is seen in only 16% of cases, yet it represents
the most common cause of mortality in PNH. The venous
system – especially atypical vessels such as the portal,
mesenteric, and hepatic veins – is more commonly
affected than is the arterial system, which makes this
patient’s case atypical.6 Furthermore, intracerebral sites are
less commonly involved than intraabdominal sites.6 The
major risk factors for thrombosis are the proportion of
PNH granulocytes (PNH clone size) and the degree of
intravascular hemolysis.5 Europeans have also been shown
to be at increased risk for thrombosis when compared to
Asian patients.1 The diagnosis of PNH is confirmed with
peripheral blood flow cytometry by detecting the absence
of GPI-APs on ≥2 lineages with a reagent known as
fluorescent aerolysin (FLAER).4
Eculizumab is the drug of choice in managing patients
with PNH. It must be administered indefinitely for a
sustained response. Two multinational phase 3 trials, the
TRIUMPH and SHEPHERD trials, concluded that eculizumab
is highly effective in stopping intravascular hemolysis,
decreasing the need for red cell transfusions with >70%
achieving transfusion independence, improving quality of
life, and reducing the risk of thrombosis.7,8 Furthermore,
patients on eculizumab and anticoagulation had a lower
thromboembolic rate than those on anticoagulation alone.

Severe anemia, thrombosis, renal insufficiency, and
dyspnea are all strong indications to initiate therapy.
Corticosteroids may improve hemoglobin levels and
reduce hemolysis, but their minimal benefit is overshadowed
by their long-term toxicity. Allogeneic stem cell transplant
is an option for patients with severe aplastic anemia or
those who are unresponsive to eculizumab therapy.4
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In this particular case, the most challenging aspect was
balancing the need for anticoagulation with the risk of
hemorrhagic stroke in a patient at high risk for poor medical
literacy and medication non-compliance. After consulting
the Neurology service, the non-malignant Hematology
service, and the Anticoagulation and Thrombosis service, it
was ultimately decided to continue the patient on anticoagulation as the risk for further thrombotic events
outweighed the risk of hemorrhagic conversion of the
subacute ischemic strokes. It was felt that warfarin, a
reversible anticoagulant, would be safer in the short term.
Verbal consent was obtained from the patient to publish
this case report.
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